Open Access<p>A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers</p>
Author(s) -
Woo Youl Kang,
Hae Won Lee,
MiRi Gwon,
Seung Il Cho,
Wang-Seob Shim,
KyungTae Lee,
Dong Heon Yang,
Sook Jin Seong,
YoungRan Yoon
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s248205
Subject(s) - linagliptin , medicine , pharmacokinetics , cmax , dipeptidyl peptidase 4 inhibitor , pharmacology , type 2 diabetes , area under the curve , diabetes mellitus , endocrinology
Fimasartan, an angiotensin II type 1 receptor blocker, and linagliptin, a dipeptidyl-peptidase-4 inhibitor, are frequently coadministered to treat patients with hypertension and diabetes, respectively. This study sought to evaluate the pharmacokinetic interactions between fimasartan and linagliptin after co-administration in healthy Korean subjects.